X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (228) 228
index medicus (167) 167
rituximab (112) 112
refractory wegeners-granulomatosis (86) 86
rheumatology (81) 81
vasculitis (72) 72
immunosuppressive agents - therapeutic use (70) 70
male (68) 68
treatment outcome (68) 68
adult (66) 66
female (63) 63
middle aged (57) 57
antibodies, monoclonal - therapeutic use (55) 55
cyclophosphamide (53) 53
antibody-associated vasculitis (50) 50
anca-associated vasculitis (48) 48
churg-strauss-syndrome (47) 47
immunologic factors - therapeutic use (46) 46
wegeners-granulomatosis (46) 46
systemic vasculitis (43) 43
therapy (42) 42
aged (41) 41
care and treatment (40) 40
efficacy (38) 38
microscopic polyangiitis (38) 38
immunology (37) 37
remission induction (37) 37
systemic-lupus-erythematosus (37) 37
medicine & public health (35) 35
randomized-trial (35) 35
rheumatoid-arthritis (35) 35
term-follow-up (34) 34
infliximab (32) 32
medicine, general & internal (32) 32
anti-neutrophil cytoplasmic antibody-associated vasculitis - drug therapy (30) 30
antibodies, monoclonal, murine-derived (30) 30
retrospective studies (30) 30
antibodies, monoclonal, murine-derived - therapeutic use (29) 29
refractory uveitis (29) 29
animals (28) 28
disease (28) 28
granulomatosis with polyangiitis (28) 28
granulomatosis with polyangiitis - drug therapy (28) 28
remission (28) 28
refractory granulomatosis (27) 27
uveitis (26) 26
vasculitis - immunology (26) 26
cyclophosphamide - therapeutic use (25) 25
wegener's granulomatosis (25) 25
double-blind (24) 24
mycophenolate-mofetil (24) 24
refractory (24) 24
vasculitis - drug therapy (24) 24
anca (23) 23
corticosteroids (23) 23
tnf-alpha blockade (23) 23
vasculitis - therapy (23) 23
juvenile idiopathic arthritis (22) 22
pharmacology & pharmacy (22) 22
treatment (22) 22
tumor necrosis factor-alpha - antagonists & inhibitors (22) 22
behcets-disease (21) 21
risk factors (21) 21
inflammation (20) 20
intravenous immunoglobulin (20) 20
ophthalmology (20) 20
polyarteritis-nodosa (20) 20
adolescent (19) 19
child (19) 19
drug therapy (19) 19
internal medicine (19) 19
recurrence (19) 19
urology & nephrology (19) 19
uveitis - drug therapy (19) 19
young adult (19) 19
abridged index medicus (18) 18
autoimmune diseases - drug therapy (18) 18
diagnosis (18) 18
immunotherapy (18) 18
methotrexate (18) 18
research (18) 18
tumor-necrosis-factor (18) 18
antineutrophil cytoplasmic antibodies (17) 17
glucocorticoids - therapeutic use (17) 17
maintenance therapy (17) 17
antineutrophil cytoplasmic autoantibodies (16) 16
drug therapy, combination (16) 16
small-vessel vasculitis (16) 16
adrenal cortex hormones - therapeutic use (15) 15
antibodies, antineutrophil cytoplasmic - immunology (15) 15
clinical trials as topic (15) 15
dermatology (15) 15
immunosuppressive agents - administration & dosage (15) 15
necrosis-factor-alpha (15) 15
plasma exchange (15) 15
review (15) 15
antibodies, monoclonal - adverse effects (14) 14
autoimmune diseases (14) 14
biologics (14) 14
etanercept (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Rheumatology, ISSN 0770-3198, 6/2014, Volume 33, Issue 6, pp. 841 - 848
Journal Article
Journal Article
Rheumatology (United Kingdom), ISSN 1462-0324, 11/2013, Volume 52, Issue 11, pp. 2041 - 2047
Objective. Rituximab (RTX) is an anti-CD20 antibody used successfully in granulomatosis with polyangiitis (GPA) for induction and maintenance of remission. Our... 
Hypogammaglobulinaemia | Infection | Granulomatosis with polyangiitis | Rituximab | Maintenance | Safety | ANCA-associated vasculitis | WEGENERS-GRANULOMATOSIS | infection | ANTIBODY-ASSOCIATED VASCULITIS | CYCLOPHOSPHAMIDE | MICROSCOPIC POLYANGIITIS | CONSENSUS CONFERENCE | FOLLOW-UP | INDUCTION | RHEUMATOLOGY | granulomatosis with polyangiitis | REFRACTORY GRANULOMATOSIS | safety | hypogammaglobulinaemia | maintenance | rituximab | REMISSION | Drug Evaluation - methods | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Young Adult | Granulomatosis with Polyangiitis - immunology | Adult | Female | Opportunistic Infections - immunology | Retrospective Studies | Immunosuppressive Agents - administration & dosage | Opportunistic Infections - complications | Drug Administration Schedule | Risk Factors | Treatment Outcome | CD4 Lymphocyte Count | Remission Induction | Adolescent | Granulomatosis with Polyangiitis - drug therapy | Immunosuppressive Agents - adverse effects | Aged | Immunocompromised Host | Antibodies, Monoclonal, Murine-Derived - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Granulomatosis with Polyangiitis - complications | Rheumatology: 759 | VDP | Reumatologi: 759 | Klinisk medisinske fag: 750 | Vaskulitt | Medisinske Fag: 700 | Clinical medical disciplines: 750 | Medical disciplines: 700
Journal Article
Journal Article
International Journal of Rheumatic Diseases, ISSN 1756-1841, 10/2017, Volume 20, Issue 10, pp. 1593 - 1605
Journal Article
Journal Article
Rheumatology International, ISSN 0172-8172, 6/2015, Volume 35, Issue 6, pp. 1083 - 1092
Journal Article
Journal Article